JP2023513800A5 - - Google Patents

Info

Publication number
JP2023513800A5
JP2023513800A5 JP2022549159A JP2022549159A JP2023513800A5 JP 2023513800 A5 JP2023513800 A5 JP 2023513800A5 JP 2022549159 A JP2022549159 A JP 2022549159A JP 2022549159 A JP2022549159 A JP 2022549159A JP 2023513800 A5 JP2023513800 A5 JP 2023513800A5
Authority
JP
Japan
Prior art keywords
domain
cdr
sequence number
seq
clone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022549159A
Other languages
English (en)
Japanese (ja)
Other versions
JP7840569B2 (ja
JP2023513800A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/018276 external-priority patent/WO2021167915A1/en
Publication of JP2023513800A publication Critical patent/JP2023513800A/ja
Publication of JP2023513800A5 publication Critical patent/JP2023513800A5/ja
Priority to JP2026043039A priority Critical patent/JP2026091871A/ja
Application granted granted Critical
Publication of JP7840569B2 publication Critical patent/JP7840569B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022549159A 2020-02-17 2021-02-17 ヒト4-1bbアゴニスト抗体およびその使用方法 Active JP7840569B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026043039A JP2026091871A (ja) 2020-02-17 2026-03-17 ヒト4-1bbアゴニスト抗体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062977658P 2020-02-17 2020-02-17
US62/977,658 2020-02-17
PCT/US2021/018276 WO2021167915A1 (en) 2020-02-17 2021-02-17 Human 4-1bb agonist antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026043039A Division JP2026091871A (ja) 2020-02-17 2026-03-17 ヒト4-1bbアゴニスト抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2023513800A JP2023513800A (ja) 2023-04-03
JP2023513800A5 true JP2023513800A5 (cg-RX-API-DMAC7.html) 2024-02-21
JP7840569B2 JP7840569B2 (ja) 2026-04-06

Family

ID=77391204

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022549159A Active JP7840569B2 (ja) 2020-02-17 2021-02-17 ヒト4-1bbアゴニスト抗体およびその使用方法
JP2026043039A Pending JP2026091871A (ja) 2020-02-17 2026-03-17 ヒト4-1bbアゴニスト抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026043039A Pending JP2026091871A (ja) 2020-02-17 2026-03-17 ヒト4-1bbアゴニスト抗体およびその使用方法

Country Status (8)

Country Link
US (2) US12649797B2 (cg-RX-API-DMAC7.html)
EP (1) EP4106880A4 (cg-RX-API-DMAC7.html)
JP (2) JP7840569B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220143904A (cg-RX-API-DMAC7.html)
CN (2) CN115335123B (cg-RX-API-DMAC7.html)
AU (1) AU2021224793A1 (cg-RX-API-DMAC7.html)
CA (1) CA3167218A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021167915A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
CA2434668A1 (en) * 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
EP2021371A2 (en) * 2006-04-28 2009-02-11 Oregon Health and Science University Monoclonal antibodies specific for pancreatic endocrine, exocrine or ductal cells
US20090297530A1 (en) 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
EP2899212B1 (en) 2009-03-30 2017-07-19 Edimer Biotech S.a. Preparation of isolated agonist anti-EDAR monoclonal antibodies
AR092662A1 (es) * 2012-09-24 2015-04-29 Gilead Sciences Inc Anticuerpos anti-ddr1
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9469686B2 (en) * 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
US20150147333A1 (en) * 2013-10-18 2015-05-28 Genentech, Inc. Anti-rspo antibodies and methods of use
AP2016009222A0 (en) * 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
ES2980788T3 (es) 2014-04-10 2024-10-03 H Lee Moffitt Cancer Ct & Res Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva
GB201410520D0 (en) 2014-06-12 2014-07-30 Univ London Queen Mary Antibody
AU2016222216A1 (en) * 2015-02-19 2017-09-14 Emergent Biosolutions Canada Inc. Humanized filovirus antibodies and uses thereof
US10875921B2 (en) * 2016-05-27 2020-12-29 Abbvie Biotherapeutics Inc. Anti-4-1BB antibodies and their uses
TWI831365B (zh) * 2017-01-10 2024-02-01 國立大學法人山口大學 抗gpc3抗體
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
TW201932491A (zh) 2018-01-22 2019-08-16 大陸商江蘇恆瑞醫藥股份有限公司 抗4-1bb抗體、其抗原結合片段及其醫藥用途
EA202092319A1 (ru) 2018-03-29 2021-03-04 Айовэнс Байотерапьютикс, Инк. Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof

Similar Documents

Publication Publication Date Title
CN113603783B (zh) 蛋白酶可切割的双特异性抗体及其用途
EP3237006B1 (en) Bispecific tetravalent antibodies and methods of making and using thereof
CN103987731B (zh) Agr2阻断抗体及其用途
JP2023539501A5 (cg-RX-API-DMAC7.html)
JP2022031784A5 (cg-RX-API-DMAC7.html)
WO2018133842A1 (zh) 人程序性死亡受体pd-1的单克隆抗体及其片段
CN116948035A (zh) 多特异性抗体及其制备和使用方法
JP2022512891A5 (cg-RX-API-DMAC7.html)
JP2022550243A5 (cg-RX-API-DMAC7.html)
JP2022545741A5 (cg-RX-API-DMAC7.html)
US20230340119A1 (en) Composition of triax antibodies and method of making and using thereof
JP2022521305A (ja) 抗pd-l1抗体及びその使用
JP2024519078A5 (cg-RX-API-DMAC7.html)
WO2018027147A1 (en) Affinity maturated tag72 specific single chain antibodies
EP4417622A1 (en) Anti-cd26 antibody and use thereof
JP2024528987A5 (cg-RX-API-DMAC7.html)
WO2023143273A1 (zh) 新型长效化和高活性且更安全的抗体构建体
TW202146446A (zh) 一種抗pd-l1和egfr的四價雙特異性抗體
JP2024508597A5 (cg-RX-API-DMAC7.html)
CN115335123A (zh) 人4-1bb激动剂抗体及其使用方法
HK40128164A (zh) Triax抗体的组合物及其制备和使用方法
HK40128165A (en) Composition of triax antibodies and method of making and using thereof
WO2024152963A1 (zh) 抗cd3的人源化抗体及其应用
WO2024037627A1 (zh) 一种双特异性抗体及其应用
HK40123160A (en) Pharmaceutical use of anti-pd-1-anti-vegfa bispecific antibody